Nanoparticle Targeting with Antibodies in the Central Nervous System.
| Autor: | Lee JH; Department of Biomedical Engineering, Yale University, New Haven, CT, USA., Chapman DV; Department of Biomedical Engineering, Yale University, New Haven, CT, USA., Saltzman WM; Department of Biomedical Engineering, Yale University, New Haven, CT, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BME frontiers [BME Front] 2023 Mar 31; Vol. 4, pp. 0012. Date of Electronic Publication: 2023 Mar 31 (Print Publication: 2023). |
| DOI: | 10.34133/bmef.0012 |
| Abstrakt: | Treatments for disease in the central nervous system (CNS) are limited because of difficulties in agent penetration through the blood-brain barrier, achieving optimal dosing, and mitigating off-target effects. The prospect of precision medicine in CNS treatment suggests an opportunity for therapeutic nanotechnology, which offers tunability and adaptability to address specific diseases as well as targetability when combined with antibodies (Abs). Here, we review the strategies to attach Abs to nanoparticles (NPs), including conventional approaches of chemisorption and physisorption as well as attempts to combine irreversible Ab immobilization with controlled orientation. We also summarize trends that have been observed through studies of systemically delivered Ab-NP conjugates in animals. Finally, we discuss the future outlook for Ab-NPs to deliver therapeutics into the CNS. Competing Interests: Competing interests: The authors declare that they have no competing interests. (Copyright © 2023 Ju Hyun Lee et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|